<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850704</url>
  </required_header>
  <id_info>
    <org_study_id>2019EX023</org_study_id>
    <nct_id>NCT03850704</nct_id>
  </id_info>
  <brief_title>Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <brief_summary>
    <textblock>
      This is an individual patient, expanded access protocol using Selinexor and dexamethasone&#xD;
      (&quot;Sd&quot;) for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male,&#xD;
      &quot;19023-UMN-01&quot; weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after&#xD;
      numerous treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selinexor is an oral, first in class, slowly reversible, potent and Selective Inhibitor of&#xD;
      Nuclear Export (SINE) compound that specifically blocks Exportin 1 (XPO1). It is one of the&#xD;
      most promising investigational drugs available for this patient with clear risk and benefit&#xD;
      assessment favoring potential benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients having relapsed/refractory multiple myeloma and neuropathy (or who are&#xD;
             otherwise unable to tolerate bortezomib)&#xD;
&#xD;
          -  Aged 18 years and older&#xD;
&#xD;
          -  Patient able to provide written, informed consent to participate in and follow the&#xD;
             KEAP Treatment Plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to selinexor or any excipients.&#xD;
&#xD;
          -  Patient receiving any other investigational agent.&#xD;
&#xD;
          -  Any concurrent uncontrolled and active medical condition or disease (e.g.,&#xD;
             uncontrolled active hypertension, uncontrolled active diabetes, active systemic&#xD;
             infection, etc.).&#xD;
&#xD;
          -  Known intolerance, hypersensitivity, or contraindication to glucocorticoids.&#xD;
&#xD;
          -  Active graft versus host disease (after allogeneic stem cell transplantation).&#xD;
&#xD;
          -  Active, unstable cardiovascular function:&#xD;
&#xD;
               -  Symptomatic ischemia, or uncontrolled clinically significant conduction&#xD;
                  abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics)&#xD;
&#xD;
               -  Congestive heart failure of New York Heart Association Class â‰¥ 3 or known&#xD;
                  leftventricular ejection fraction &lt; 40%, or&#xD;
&#xD;
               -  Myocardial infarction within 3 months prior to C1D1.&#xD;
&#xD;
          -  Significant renal impairment with ongoing dialysis treatment&#xD;
&#xD;
          -  Active gastrointestinal dysfunction interfering with the patient's ability to swallow&#xD;
             tablets, or any active gastrointestinal dysfunction that could, in the treating&#xD;
             physician's opinion, interfere with absorption of treatment.&#xD;
&#xD;
          -  Any active, serious psychiatric, medical, or other conditions/situations which, in the&#xD;
             treating physician's opinion, could compromise the patient's safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Erica Warlick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology, Oncology and Transplantation, University of Minnesota</affiliation>
  </overall_official>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

